174 related articles for article (PubMed ID: 8920798)
21. Tamoxifen mediated human endometrial carcinogenesis may not involve estrogenic pathways: a preliminary note.
Kuwashima Y; Kurosumi M; Kobayashi Y; Tanuma J; Suemasu K; Higashi Y; Kasamatsu T; Shiromizu K; Matsuzawa M; Kishi K
Anticancer Res; 1996; 16(5A):2993-6. PubMed ID: 8917418
[TBL] [Abstract][Full Text] [Related]
22. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer.
Deligdisch L; Kalir T; Cohen CJ; de Latour M; Le Bouedec G; Penault-Llorca F
Gynecol Oncol; 2000 Aug; 78(2):181-6. PubMed ID: 10926800
[TBL] [Abstract][Full Text] [Related]
23. Is tamoxifen associated with high-risk endometrial carcinomas? A retrospective case series of 196 women with endometrial cancer.
Rieck GC; Freites ON; Williams S
J Obstet Gynaecol; 2005 Jan; 25(1):39-41. PubMed ID: 16147692
[TBL] [Abstract][Full Text] [Related]
24. [Histological analysis of endometrial polyps in breast cancer patients treated with tamoxifen (nolvadex)].
Ivanova V; Karaivanov M; Raĭcheva S; Marinov E; Gorchev G
Akush Ginekol (Sofiia); 2004; 43(2):33-6. PubMed ID: 15185527
[TBL] [Abstract][Full Text] [Related]
25. Secretory endometrial adenocarcinoma in a tamoxifen user with breast cancer after menopause.
Wu CJ; Peng YJ; Yu MH; Chen CH
Taiwan J Obstet Gynecol; 2007 Mar; 46(1):88-90. PubMed ID: 17389201
[No Abstract] [Full Text] [Related]
26. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features.
Barakat RR; Wong G; Curtin JP; Vlamis V; Hoskins WJ
Gynecol Oncol; 1994 Nov; 55(2):164-8. PubMed ID: 7959278
[TBL] [Abstract][Full Text] [Related]
27. Genomic profile of endometrial tumors depends on morphological subtype, not on tamoxifen exposure.
Fles R; Hoogendoorn WE; Platteel I; Scheerman CE; de Leeuw-Mantel G; Mourits MJ; Hollema H; van Leeuwen FE; van Boven HH; Nederlof PM
Genes Chromosomes Cancer; 2010 Aug; 49(8):699-710. PubMed ID: 20544844
[TBL] [Abstract][Full Text] [Related]
28. Iatrogenic endometrial megapolyps in women with breast carcinoma.
Berezowsky J; Chalvardjian A; Murray D
Obstet Gynecol; 1994 Oct; 84(4 Pt 2):727-30. PubMed ID: 9205466
[TBL] [Abstract][Full Text] [Related]
29. Tamoxifen and endometrial pathologies: a prospective study.
Seoud M; Shamseddine A; Khalil A; Salem Z; Saghir N; Bikhazi K; Bitar N; Azar G; Kaspar H
Gynecol Oncol; 1999 Oct; 75(1):15-9. PubMed ID: 10502419
[TBL] [Abstract][Full Text] [Related]
30. A clinicopathologic study on patients with endometrial cancer after adjuvant tamoxifen treatment for breast cancer: a single center experience.
Ravazoula P; Androutsopoulos G; Zyli P; Michail G; Kardamakis DM; Kourounis G
Breast J; 2006; 12(6):578-84. PubMed ID: 17238994
[No Abstract] [Full Text] [Related]
31. Malignant mixed mesodermal tumor after tamoxifen therapy for breast cancer.
Hubalek M; Ramoni A; Mueller-Holzner E; Marth C
Gynecol Oncol; 2004 Oct; 95(1):264-6. PubMed ID: 15385144
[TBL] [Abstract][Full Text] [Related]
32. [Primary multiple neoplasm of the endometrium and adjuvant hormone therapy in patients with breast cancer].
Bakhidze EV; Maksimov SIa; Barash NIu; Berstein LM; Semiglazov VF; Sheĭko EV; Novik VI
Vopr Onkol; 1998; 44(2):170-4. PubMed ID: 9615821
[TBL] [Abstract][Full Text] [Related]
33. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study.
Wilder JL; Shajahan S; Khattar NH; Wilder DM; Yin J; Rushing RS; Beaven R; Kaetzel C; Ueland FR; van Nagell JR; Kryscio RJ; Lele SM
Gynecol Oncol; 2004 Feb; 92(2):553-8. PubMed ID: 14766247
[TBL] [Abstract][Full Text] [Related]
34. A comparative analysis of Ki-67, p53, and p21WAF1CIP1 expression in tamoxifen associated endometrial carcinomas.
Ramondetta LM; Palazzo JP; Dunton CJ; Kovatich AJ; Carlson JA
Anticancer Res; 1998; 18(6B):4661-5. PubMed ID: 9891537
[TBL] [Abstract][Full Text] [Related]
35. Gynecologic tumors in tamoxifen-treated women with breast cancer.
Seoud MA; Johnson J; Weed JC
Obstet Gynecol; 1993 Aug; 82(2):165-9. PubMed ID: 8393156
[TBL] [Abstract][Full Text] [Related]
36. Endometrial pathology at dilatation and curettage in breast cancer patients: comparison of tamoxifen users and nonusers.
Gibson LE; Barakat RR; Venkatraman ES; Hoskins WJ
Cancer J Sci Am; 1996; 2(1):35-8. PubMed ID: 9166496
[TBL] [Abstract][Full Text] [Related]
37. A case-case analysis of factors related to overexpression of p53 in endometrial cancer following breast cancer.
Olson SH; Finstad CL; Harlap S; Kurian L; Saigo PE; Barakat RR
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):815-7. PubMed ID: 9332764
[TBL] [Abstract][Full Text] [Related]
38. [Pathology of the endometrium in breast cancer patients treated with tamoxifen (nolvadex)].
Ivanova V; Karaivanov M; Marinov E; Gorchev G; Velkova A; Khristova P
Akush Ginekol (Sofiia); 2003; 42(5):3-8. PubMed ID: 14682005
[TBL] [Abstract][Full Text] [Related]
39. Endometrial cancer in patients with breast carcinoma treated with tamoxifen: report of two cases and the literature overview.
Sliwińska M; Wojtacki J; Sliwiński W
Med Sci Monit; 2000; 6(2):399-406. PubMed ID: 11208346
[TBL] [Abstract][Full Text] [Related]
40. [Endometrial cancers arising in polyps associated with tamoxifen use].
Mbatsogo BA; Le Bouëdec G; Michy T; Bourdel N; Fouilloux G; Dauplat J
Gynecol Obstet Fertil; 2005 Dec; 33(12):975-9. PubMed ID: 16321556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
